Publications by authors named "Michael Nishimura"

Claim this Profile
H
HS-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response.
Nathaniel Oberholtzer, Paramita Chakraborty, Mohamed Faisal Kassir, James Dressman, Satyajit Das, Michael I Nishimura

Sci Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.
Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani, Michael I Nishimura

J Immunother Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR.
Stefan Barisic, Elena Cherkasova, Rosa Nadal, Xin Tian, Long Chen, Michael I Nishimura

Mol Ther Methods Clin Dev· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEETING HIGHLIGHTS: THE THIRD MARIE SKŁODOWSKA-CURIE SYMPOSIUM ON CANCER RESEARCH AND CARE AT ROSWELL PARK COMPREHENSIVE CANCER CENTER, BUFFALO, NY, SEPTEMBER 20-22, 2023.
Pawel Kalinski, Kathleen M Kokolus, Rami Azrak, Mikhail Y Berezin, Renier Brentjens, Michael I Nishimura

Wiad Lek· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior.
Siao-Yi Wang, Gina M Scurti, Annika V Dalheim, Suzanne Quinn, Patrick J Stiff, Michael I Nishimura

Blood Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance.
Xueliang Gao, Yongxia Wu, Joel M Chick, Andrea Abbott, Baishan Jiang, Michael I Nishimura

Cell Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A class-mismatched TCR bypasses MHC restriction via an unorthodox but fully functional binding geometry.
Nishant K Singh, Jesus A Alonso, Jason R Devlin, Grant L J Keller, George I Gray, Michael I Nishimura

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
Aleksandra Vuchkovska, David G Glanville, Gina M Scurti, Michael I Nishimura, Paula White

Immunology· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic Modification of T Cells for the Immunotherapy of Cancer.
Suzanne Quinn, Natasha Lenart, Victoria Dronzek, Gina M Scurti, Nasheed M Hossain, Michael I Nishimura

Vaccines (Basel)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human CD36 monocytes induce Foxp3  CD25 T cells with regulatory functions from CD4 and CD8 subsets.
Jessica G Lee, Kathleen E Jaeger, Yoichi Seki, Yi Wei Lim, Christina Cunha, Michael Nishimura

Immunology· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma reactive TCR-modified T cells generated without activation retain a less differentiated phenotype and mediate a superior in vivo response.
Siao-Yi Wang, Tamson V Moore, Annika V Dalheim, Gina M Scurti, Michael I Nishimura

Sci Rep· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
Tamson V Moore, Gina M Scurti, Matthew DeJong, Siao-Yi Wang, Annika V Dalheim, Michael I Nishimura

Mol Ther Oncolytics· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelin-1-Mediated Drug Resistance in -Mutant Non-Small Cell Lung Carcinoma.
Inés Pulido, Stephen Ollosi, Salvador Aparisi, Jeffrey H Becker, Alicia Aliena-Valero, Michael I Nishimura

Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of human CD4 T cell populations with distinct antitumor activity.
Michelle H Nelson, Hannah M Knochelmann, Stefanie R Bailey, Logan W Huff, Jacob S Bowers, Michael I Nishimura

Sci Adv· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved MHC II epitope prediction - a step towards personalized medicine.
Tamson V Moore, Michael I Nishimura

Nat Rev Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late Events After CD-19 CAR-T Treatment.
Nasheed M Hossain, Michael I Nishimura

Biol Blood Marrow Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy.
Timothy T Spear, Brian D Evavold, Brian M Baker, Michael I Nishimura

Cancer Immunol Immunother· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Cancer with Genetically Engineered TCR T Cells.
Thomas W Smith, Michael I Nishimura

Recent Results Cancer Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transgenerational transfer of gene-modified T cells.
Cormac Cosgrove, Emilia R Dellacecca, Joost H van den Berg, John B Haanen, Michael I Nishimura

J Immunother Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells.
Paramita Chakraborty, Shilpak Chatterjee, Pravin Kesarwani, Krishnamurthy Thyagarajan, Supinya Iamsawat, Michael I Nishimura

J Biol Chem· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving T Cell Receptor On-Target Specificity via Structure-Guided Design.
Lance M Hellman, Kendra C Foley, Nishant K Singh, Jesus A Alonso, Timothy P Riley, Michael I Nishimura

Mol Ther· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling.
Eun-Kyoung Breuer, Daniela Fukushiro-Lopes, Annika Dalheim, Miranda Burnette, Jeremiah Zartman, Michael I Nishimura

Cell Death Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.
Jonathan M Eby, Angela R Smith, Timothy P Riley, Cormac Cosgrove, Christian M Ankney, Michael I Nishimura

Pigment Cell Melanoma Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell receptor cross-reactivity expanded by dramatic peptide-MHC adaptability.
Timothy P Riley, Lance M Hellman, Marvin H Gee, Juan L Mendoza, Jesus A Alonso, Michael I Nishimura

Nat Chem Biol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An adaptive dose-finding design based on both safety and immunologic responses in cancer clinical trials.
Cody Chiuzan, Elizabeth Garrett-Mayer, Michael Nishimura

Stat Biopharm Res· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis